Multiple Sclerosis

Organizer(s): Trevor J. Kilpatrick, Brenda Banwell and Hartmut Wekerle

Sponsored by Biogen Idec and the National Multiple Sclerosis Society

For important information on the coronavirus, please click here

Summary of Meeting:

Multiple sclerosis (MS) is a complex disease in which genetic, environmental and stochastic factors all play a part to induce aberrant interactions between the immune system and neural cells, ultimately transforming into progressive neurological disability. Our understanding of MS is rapidly evolving, and multiple areas of research are showing great promise of future treatment or cure. However, further progress will depend on establishing a deep understanding of the underlying disease mechanisms. With this in mind, this meeting aims to: 1) Define integrated approaches by which to study disease pathogenesis, which represents a critical barrier to progress in the field; 2) Provide an up-to-date perspective on molecular pathogenesis and how this might be used to optimize patient management; 3) Define state-of-the-art technologies by which to quantitate disease burden; 4) Discuss key elements concerning the concept of disease heterogeneity and how emergent approaches to disease stratification can optimize management strategies; and 5) Provide perspectives concerning the potential therapeutic applications of neuroprotective, regenerative and bioengineering-based strategies, and how these might complement immunotherapy. Speakers have been carefully selected on the basis that, independent of whether they are basic scientists or clinician researchers, they each have a track record in adopting a multi-disciplinary approach that has enabled the application of discoveries in one area of endeavor to seed advances in another. We anticipate that participants will gain an understanding of how a systems biology-based approach can accelerate our knowledge base of multiple sclerosis and how that knowledge base can be successfully applied to novel clinical research and development, as well as potentiated patient care.

Scholarship Deadline: September 12 2012

Discounted Abstract Deadline: September 12 2012

Abstract Deadline: October 11 2012

Discounted Registration Deadline: November 12 2012

Abstacts when book is in proofing process

Keystone Symposia thanks our Sponsor(s) for generously supporting this meeting:

We gratefully acknowledge the generous grant for this conference provided by:

National Institute of Neurological Disorders and Stroke (NINDS)
Grant No. 1R13NS080288-01
The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Click here to view more of these organizations

Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:

Click here to view more of these organizations